SEK 0.4
(-3.61%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - SEK | 0.0% |
2022 | - SEK | 0.0% |
2021 | - SEK | 0.0% |
2020 | - SEK | 0.0% |
2019 | - SEK | 0.0% |
2018 | - SEK | 0.0% |
2017 | - SEK | 0.0% |
2016 | - SEK | 0.0% |
2015 | - SEK | 0.0% |
2014 | - SEK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - SEK | 0.0% |
2024 Q2 | - SEK | 0.0% |
2023 FY | - SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 FY | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2021 FY | - SEK | 0.0% |
2021 Q2 | - SEK | 0.0% |
2021 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 Q1 | - SEK | 0.0% |
2020 Q3 | - SEK | 0.0% |
2020 FY | - SEK | 0.0% |
2020 Q1 | - SEK | 0.0% |
2020 Q4 | - SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2019 Q1 | - SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 FY | - SEK | 0.0% |
2019 Q3 | - SEK | 0.0% |
2018 FY | - SEK | 0.0% |
2018 Q2 | - SEK | 0.0% |
2018 Q4 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 Q1 | - SEK | 0.0% |
2017 FY | - SEK | 0.0% |
2017 Q1 | - SEK | 0.0% |
2017 Q4 | - SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q2 | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2016 FY | - SEK | 0.0% |
2016 Q3 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 FY | - SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2015 Q4 | - SEK | 0.0% |
2014 Q4 | - SEK | 0.0% |
2014 FY | - SEK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AcuCort AB | - SEK | NaN% |
AlzeCure Pharma AB (publ) | - SEK | NaN% |
BioGaia AB (publ) | 8.8 Million SEK | 100.0% |
Enzymatica AB (publ) | 26.1 Million SEK | 100.0% |
Enorama Pharma AB (publ) | 436 Thousand SEK | 100.0% |
Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 100.0% |
Moberg Pharma AB (publ) | 4.73 Million SEK | 100.0% |
Nanexa AB (publ) | 4.03 Million SEK | 100.0% |
Newbury Pharmaceuticals AB (publ) | - SEK | NaN% |
ODI Pharma AB | - SEK | NaN% |
Orexo AB (publ) | 473.8 Million SEK | 100.0% |
Probi AB (publ) | 53.79 Million SEK | 100.0% |
Swedencare AB (publ) | 1.65 Billion SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 100.0% |
Toleranzia AB | 850 Thousand SEK | 100.0% |
Vivesto AB | 8.16 Million SEK | 100.0% |